Similar articles

• Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.

  Rodeghiero F, Tosetto A. Rodeghiero F, et al. Ann Intern Med. 1999 Apr 20;130(8):643-50. doi: 10.7326/0003-4819-130-8-199904200-00004. Ann Intern Med. 1999. PMID: 10215560
• A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.

  Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyák K, van Der Meer J, Prins MH, Büller HR. Middeldorp S, et al. Ann Intern Med. 2001 Sep 4;135(5):322-7. doi: 10.7326/0003-4819-135-5-200109040-00008. Ann Intern Med. 2001. PMID: 11529695
• Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

  Price DT, Ridker PM. Price DT, et al. Ann Intern Med. 1997 Nov 15;127(10):895-903. doi: 10.7326/0003-4819-127-10-199711150-00007. Ann Intern Med. 1997. PMID: 9382368 Review.
• The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece.

  Ioannou HV, Mitsis M, Eleftheriou A, Matsagas M, Nousias V, Rigopoulos C, Vartholomatos G, Kappas AM. Ioannou HV, et al. Int Angiol. 2000 Dec;19(4):314-8. Int Angiol. 2000. PMID: 11305729
• Factor V Leiden: a case study and review.

  Slusher KB. Slusher KB. Dimens Crit Care Nurs. 2010 Jan-Feb;29(1):6-10. doi: 10.1097/DCC.0b013e3181be4985. Dimens Crit Care Nurs. 2010. PMID: 20010186 Review.